These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27775073)

  • 1. p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors.
    Chiche A; Moumen M; Romagnoli M; Petit V; Lasla H; Jézéquel P; de la Grange P; Jonkers J; Deugnier MA; Glukhova MA; Faraldo MM
    Oncogene; 2017 Apr; 36(17):2355-2365. PubMed ID: 27775073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myc is required for β-catenin-mediated mammary stem cell amplification and tumorigenesis.
    Moumen M; Chiche A; Decraene C; Petit V; Gandarillas A; Deugnier MA; Glukhova MA; Faraldo MM
    Mol Cancer; 2013 Oct; 12(1):132. PubMed ID: 24171719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 controls the plasticity of mammary luminal progenitor cells downstream of Met signaling.
    Chiche A; Di-Cicco A; Sesma-Sanz L; Bresson L; de la Grange P; Glukhova MA; Faraldo MM; Deugnier MA
    Breast Cancer Res; 2019 Jan; 21(1):13. PubMed ID: 30683141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
    Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
    Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YAP and β-Catenin Cooperate to Drive Oncogenesis in Basal Breast Cancer.
    Quinn HM; Vogel R; Popp O; Mertins P; Lan L; Messerschmidt C; Landshammer A; Lisek K; Château-Joubert S; Marangoni E; Koren E; Fuchs Y; Birchmeier W
    Cancer Res; 2021 Apr; 81(8):2116-2127. PubMed ID: 33574090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crucial and novel cancer drivers in a mouse model of triple-negative breast cancer.
    Johnson JP; Kumar P; Koulnis M; Patel M; Simin K
    Cancer Genomics Proteomics; 2014; 11(3):115-26. PubMed ID: 24969692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
    Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
    Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt-responsive cancer stem cells are located close to distorted blood vessels and not in hypoxic regions in a p53-null mouse model of human breast cancer.
    Vadakkan TJ; Landua JD; Bu W; Wei W; Li F; Wong ST; Dickinson ME; Rosen JM; Lewis MT; Zhang M
    Stem Cells Transl Med; 2014 Jul; 3(7):857-66. PubMed ID: 24797826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.
    Knight JF; Lesurf R; Zhao H; Pinnaduwage D; Davis RR; Saleh SM; Zuo D; Naujokas MA; Chughtai N; Herschkowitz JI; Prat A; Mulligan AM; Muller WJ; Cardiff RD; Gregg JP; Andrulis IL; Hallett MT; Park M
    Proc Natl Acad Sci U S A; 2013 Apr; 110(14):E1301-10. PubMed ID: 23509284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression.
    Morrison CD; Allington TM; Thompson CL; Gilmore HL; Chang JC; Keri RA; Schiemann WP
    Oncotarget; 2016 Nov; 7(45):72777-72794. PubMed ID: 27626309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-6 integrin deletion delays the formation of Brca1/p53-deficient basal-like breast tumors by restricting luminal progenitor cell expansion.
    Faraldo MM; Romagnoli M; Wallon L; Dubus P; Deugnier MA; Fre S
    Breast Cancer Res; 2024 Jun; 26(1):91. PubMed ID: 38835038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity between triple negative breast cancer cells due to differential activation of Wnt and PI3K/AKT pathways.
    Martínez-Revollar G; Garay E; Martin-Tapia D; Nava P; Huerta M; Lopez-Bayghen E; Meraz-Cruz N; Segovia J; González-Mariscal L
    Exp Cell Res; 2015 Nov; 339(1):67-80. PubMed ID: 26453937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.
    Zhang S; Chung WC; Miele L; Xu K
    Cancer Biol Ther; 2014 May; 15(5):633-42. PubMed ID: 24556651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells.
    Xu J; Prosperi JR; Choudhury N; Olopade OI; Goss KH
    PLoS One; 2015; 10(2):e0117097. PubMed ID: 25658419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model.
    Kim G; Ouzounova M; Quraishi AA; Davis A; Tawakkol N; Clouthier SG; Malik F; Paulson AK; D'Angelo RC; Korkaya S; Baker TL; Esen ES; Prat A; Liu S; Kleer CG; Thomas DG; Wicha MS; Korkaya H
    Oncogene; 2015 Feb; 34(6):671-80. PubMed ID: 24531711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic loss of p53 leads to stem/progenitor cell amplification in both mammary epithelial compartments, basal and luminal.
    Chiche A; Moumen M; Petit V; Jonkers J; Medina D; Deugnier MA; Faraldo MM; Glukhova MA
    Stem Cells; 2013 Sep; 31(9):1857-67. PubMed ID: 23712598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
    Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
    Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.
    De P; Carlson JH; Wu H; Marcus A; Leyland-Jones B; Dey N
    Oncotarget; 2016 Jul; 7(28):43124-43149. PubMed ID: 27281609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elucidation of Altered Pathways in Tumor-Initiating Cells of Triple-Negative Breast Cancer: A Useful Cell Model System for Drug Screening.
    Christensen AG; Ehmsen S; Terp MG; Batra R; Alcaraz N; Baumbach J; Noer JB; Moreira J; Leth-Larsen R; Larsen MR; Ditzel HJ
    Stem Cells; 2017 Aug; 35(8):1898-1912. PubMed ID: 28600813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.